08 Oct, 2023 New Results for Patisiran Presented during HFSA ASM 2023
New 24-month results from an interim analysis of the open-label extension period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023. Findings from a post-hoc analysis of the APOLLO-B Phase 3 study that further characterize the impact of patisiran on health status and quality of life in patients with the cardiomyopathy of ATTR amyloidosis were also presented, as well as an overview of baseline characteristics of patients who enrolled in the expanded access program for patisiran.
Maurer, et al. “Primary Results from APOLLO-B Open-label Extension Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis”
Shah, et al. “Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis”
Saha, et al. “Baseline Characteristics of Patients with Transthyretin Cardiac Amyloidosis Enrolled in the Patisiran Expanded Access Program”